Immune Responses Induced by a N. Meningitidis Vaccine
“Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine”
The purpose of this study is to test whether the group B meningitis vaccine (brand name Bexseroa"c) induces immune responses against the bacteria that causes gonorrhea. Participants: Approximately 15 Individuals who are 18-25 years of age that are not pregnant, HIV negative, have no history of congenital immunologic disorder, and are not taking immune suppressive medications will be enrolled on this study at a single site, UNC-CH (University of North Carolina at Chapel Hill). Procedures (methods): Participants will receive two-doses of an FDA-approved vaccine that provides protection from N. meningitidis infection according to the recommended dosing schedule. The first vaccine dose will be given to participants at the entry visit and the second vaccine dose will be given to participants at the week 5 visit. The participants will provide samples of blood as well as mucosal surface derived samples (urine and/or swabs) at four separate visits (entry, week 5, week 6, and week 7).
Biological - Meningococcal Group B Vaccine
All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.
IGHID (Institute for Global Health and Infectious Diseases) 11911 - Cross-reactive N. Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine